National Bank Of Canada Mirati Therapeutics, Inc. Transaction History

National Bank Of Canada

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 06, 2024	BUY	$41.99 - $62.38 $19.9 Million - $29.5 Million	473,500 New	473,500 $27.8 Million
Q2 2023 Jul 26, 2023	SELL	$36.13 - $49.49 $9.11 Million - $12.5 Million	-252,200 Reduced 73.92%	89,000 $3.22 Million
Q1 2023 Apr 12, 2023	SELL	$36.54 - $54.26 $953,694 - $1.42 Million	-26,100 Reduced 7.11%	341,200 $12.7 Million
Q4 2022 Jan 24, 2023	BUY	$41.27 - $98.62 $4.76 Million - $11.4 Million	115,300 Added 45.75%	367,300 $0
Q3 2022 Oct 13, 2022	SELL	$59.5 - $86.7 $14.7 Million - $21.4 Million	-247,000 Reduced 49.5%	252,000 $17.6 Million
Q2 2022 Jul 28, 2022	BUY	$39.16 - $88.71 $19.5 Million - $44.3 Million	498,854 Added 341680.81%	499,000 $33.5 Million
Q1 2022 May 05, 2022	SELL	$75.82 - $150.97 $3.72 Million - $7.4 Million	-49,000 Reduced 99.7%	146 $12,000
Q4 2021 Jan 24, 2022	BUY	$132.01 - $190.29 $6.49 Million - $9.35 Million	49,146 New	49,146 $7.21 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of National Bank Of Canada , based on Form 13F filings with the SEC.

Stay updated on National Bank Of Canada with notifications on news.